Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jan 24, 2016 5:40pm
160 Views
Post# 24488932

RE:RE:RE:RE:RE:RE:Zenith Liquidity & RVX royalities

RE:RE:RE:RE:RE:RE:Zenith Liquidity & RVX royalitiesHi GV.

You and jkj are doing the detective work on the cash on hand. That's not an area I can help with so I appreciate your efforts. It has me very curious because if there is only a few $ in the bank they need to get out and fund raise. One of the options to raise money for R & D and admin is an IPO. So if indeed they are short of cash then I am more hopeful that Don was not just paying lip service to a ZEL IPO through a reverse take-over or whatever method he chooses. His reversal on NASDAQ was quite disturbing to me. If he does pull off an IPO soon I'll happily eat crow.

However, my sense is that he new he had to say something at the AGM about an IPO so he simply threw it in but there does not seem to be any commitment. I really have no idea but after 8 years I suspect I am right.

As I always say, I will be extremely pleased to be proven wrong!

Regarding RVX BDAZ did a post on Agora on Jan 23 at 11:07 p.m. indicating RVX has had a peer reviewed article published in the journal of Atherosclerosis. I see this as important because it adds to the scientific integrity and credibility of rvx-208's approach to BET inhibition. This should directly positively impact perceptions of both the RVX and ZEL compounds.

So at the end of the day the science will continue to drive RVX and Zenith.

If thiis post is jumbled it because I am watching Denver and the Pats!
Cheers
Toinv
Bullboard Posts